Titration

Almost every incretin agonist trial titrated. The reason is not caution for its own sake: the gastrointestinal effects of these drugs are dose-dependent and they subside with continued exposure, so a schedule that climbs slowly ends up tolerating a dose that would have been intolerable if taken first.

The practical rule people follow is to hold a step until it is uneventful before taking the next one, which means a titration schedule is a floor, not a timetable. Moving up on the calendar's schedule instead of the body's is the most common way a titration fails.

It cuts the other way too. Someone who has a bad week at a new dose can usually go back a step rather than stopping, and that option only exists if the steps were small enough to have a step to go back to.